Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

• Prif Awduron: Jenna M. Faircloth (Awdur), Neelam D. Bhatt (Awdur), Corey A. Chartan (Awdur), Ryan D. Coleman (Awdur), Natalie Villafranco (Awdur), Fadel E. Ruiz (Awdur), Raysa Morales-Demori (Awdur), Elise Whalen (Awdur), Erin Ely (Awdur), Rozmeen Fombin (Awdur), Nidhy P. Varghese (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient's and caregiver's quality of life because of...